Joseph Horrigan Joins AMO Pharma as Chief Medical Officer
Company further expands leadership team with new VP of Clinical Operations and Head of Pharmaceutical Science and Manufacturing
LONDON and PHILADELPHIA, April 18, 2016 -- (Healthcare Sales & Marketing Network) -- AMO Pharma Limited ("AMO Pharma&qu... Biopharmaceuticals, PersonnelAMO Pharma, fragile X syndrome, myotonic dystrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Fragile X Syndrome | Marketing | Pharmaceuticals | Reflex Sympathetic Dystrophy | Science